Next Article in Journal
Addressing Immunization Inequity—What Have the International Community and India Learned over 35 Years?
Previous Article in Journal
Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 4
10.3390/vaccines11040789
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis

by
Qian Zhou
1,2,
Yihuang Liu
1,2,
Furong Zeng
3,
Yu Meng
1,2,
Hong Liu
1,2 and
Guangtong Deng
1,2,*
1
Hunan Key Laboratory of Skin Cancer and Psoriasis, Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China
2
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China
3
Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(4), 789; https://doi.org/10.3390/vaccines11040789
Submission received: 21 January 2023 / Revised: 24 March 2023 / Accepted: 30 March 2023 / Published: 4 April 2023
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Review Reports Versions Notes

Abstract

:
Objective: To evaluate the potential factors for predicting seroconversion due to the coronavirus disease 2019 (COVID-19) vaccine in people living with HIV (PLWH). Method: We searched the PubMed, Embase and Cochrane databases for eligible studies published from inception to 13th September 2022 on the predictors of serologic response to the COVID-19 vaccine among PLWH. This meta-analysis was registered with PROSPERO (CRD42022359603). Results: A total of 23 studies comprising 4428 PLWH were included in the meta-analysis. Pooled data demonstrated that seroconversion was about 4.6 times in patients with high CD4 T-cell counts (odds ratio (OR) = 4.64, 95% CI 2.63 to 8.19) compared with those with low CD4 T-cell counts. Seroconversion was about 17.5 times in patients receiving mRNA COVID-19 vaccines (OR = 17.48, 95% CI 6.16 to 49.55) compared with those receiving other types of COVID-19 vaccines. There were no differences in seroconversion among patients with different ages, gender, HIV viral load, comorbidities, days after complete vaccination, and mRNA type. Subgroup analyses further validated our findings about the predictive value of CD4 T-cell counts for seroconversion due to COVID-19 vaccines in PLWH (OR range, 2.30 to 9.59). Conclusions: The CD4 T-cell counts were associated with seroconversion in COVID-19 vaccinated PLWH. Precautions should be emphasized in these patients with low CD4 T-cell counts, even after a complete course of vaccination.

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic ravaged the globe. Vaccination has become the paramount method for the prevention of worse outcomes, including severe COVID-19 and death during or in SARS-CoV-2 infection [1]. People living with HIV(PLWH) are at higher risk of these worse outcomes due to immunosuppression and its comorbidities [2,3,4,5]. Therefore, PLWH are given priority for COVID-19 vaccination. Accumulating studies demonstrated that PLWH had a lower efficacy of COVID-19 vaccines than the general population [6,7,8]. With the implementation of supplemental vaccination among PLWH [9], it is important to identify the potential predictors for seroconversion due to the COVID-19 vaccine in PLWH. However, the potential factors for predicting seroconversion after the COVID-19 vaccine in PLWH were not completely understood.
Increasing individual studies have attempted to identify the factors associated with the effectiveness of vaccination against COVID-19 [10,11,12]. For example, Anais et al. [13] found that the seroconversion rate was slightly lower among PLWH with CD4 T-cell counts of <350 cell/mm3 and dramatically reduced among those with CD4 T-cell counts of <200 cell/mm3. Moreover, the type of vaccine, the presence of comorbidities, and HIV status might preclude the development of a protective immunological response. However, the lack of studies with large sample sizes highlights the importance of a comprehensive analysis of the potential predictors for seroconversion due to the COVID-19 vaccine in PLWH.
Thus, this systematic review and meta-analysis was to provide a review of the potential factors associated with seroconversion to COVID-19 vaccines among PLWH. We extracted data from observational studies, and the factors included age, gender, CD4 T-cell count, HIV viral load, comorbidities, days after complete vaccination, and vaccine type and were evaluated with respect to the seroconversion rate in PLWH after COVID-19 vaccination. Our findings will help to plan better prevention strategies for this frail population.

2. Methods

We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRIMSA) guidelines [14]. The protocol of our meta-analysis has been submitted to the International Prospective Register of Systematic Reviews (PROSPERO). The registration number of PROSPERO is CRD42022359603.

2.1. Search Strategy

The PubMed, Embase and Cochrane Library databases were searched for relevant studies from the databases’ inception to 13th September 2022 using the following search terms: (corona[ti] OR covid*[ti] OR sars[ti] OR severe acute respiratory syndrome[ti] OR ncov*[ti] OR “severe acute respiratory syndrome coronavirus 2” [Supplementary Concept] OR “COVID-19” [Supplementary Concept] OR (wuhan[tiab] AND coronavirus[tiab]) OR (wuhan[tiab] AND pneumonia virus[tiab]) OR COVID19[tiab] OR COVID-19[tiab] OR coronavirus 2019[tiab] OR SARS-CoV-2[tiab] OR SARS2[tiab] OR SARS-2[tiab] OR “severe acute respiratory syndrome 2”[tiab] OR 2019-nCoV[tiab] OR (novel coronavirus[tiab] AND 2019[tiab]) NOT (animals[mesh] NOT humans[mesh])) AND (“Vaccines”[MeSH] OR “vaccination”[MeSH] OR vaccine[All Fields] OR vaccination[All Fields] OR vaccin*[All Fields]) AND (“HIV Infections” [MeSH] OR “HIV”[MeSH] OR “hiv”[tw] OR hiv infect*[tw] OR “human immunodeficiency virus”[tw] OR “human immunedeficiency virus”[tw] OR “human immuno-deficiency virus”[tw] OR “human immune-deficiency virus”[tw] OR ((human immun*) AND (“deficiency virus”[tw])) OR “acquired immunodeficiency syndrome”[tw] OR “acquired immunedeficiency syndrome”[tw] OR “acquired immuno-deficiency syndrome”[tw] OR “acquired immune-deficiency syndrome”[tw] OR ((acquired immun*) AND (“deficiency syndrome”[tw]))). No language restrictions were imposed. The full details of the search strategies can be found in Table S1.

2.2. Inclusion and Exclusion Criteria

The study selection was conducted in three steps: removing the initial deduplication, screening titles and abstracts, and reviewing the full text of the potentially eligible articles. Two reviewers (Q.Z. and Y.L.) independently evaluated eligibility, and the discrepancies were solved by a third investigator (G.D.). Articles were included for analysis if they met the following criteria: (1) cohort studies or randomized controlled trials; (2) patients living with HIV; (3) the odds ratio (OR) of potential predictors of seroconversion due to COVID-19 vaccine was reported, or the OR could be calculated according to the data from the studies. There were no restrictions regarding age, sex or duration of the study. The cohort studies were defined as those that sampled participants based on exposure, followed-up participants over time, and ascertained the outcomes [15]. Case reports, case series, and studies with data inaccessible from the corresponding authors were excluded.

2.3. Data Extraction and Quality Assessment

Two investigators (Q.Z. and Y.L.) independently extracted data based on a predetermined proforma in Microsoft Excel. The following information was recorded for the studies: the first author, publication year, country, study type, data source, patient number, vaccine type, vaccine dose, potential predictors for seroconversion due to the COVID-19 vaccine, multivariable analysis, COVID-19 history, and adjustment parameters. We used the Cochrane Risk of Bias 2 tool to assess the risk of bias for the randomized controlled studies [16], while the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool was used for the comparative cohort studies [17]. For the Cochrane Risk of Bias 2 tool, the risk of bias judgment per study is noted as low risk when all the domains are judged as being a low risk of bias, noted with some concerns when one or more domains are judged as some concerns, or high risk when at least one domain is judged as being at a high risk of bias, or when multiple domains are judged as some concerns. During our search, 17 eligible comparative cohort studies were included. For the ROBINS-I tool, the risk of bias judgment per study is noted as low risk when all domains are judged as being at low risk of bias, moderate risk when one domain is judged as a moderate risk of bias, serious risk when one domain is judged as serious risk of bias, or critical risk of bias when one domain is judged as being at critical risk of bias. Only one randomized study was founded in our study. The risk of bias for non-comparative cohort studies was regarded as a high risk of bias. We rated the quality of evidence according to the grading of recommendations, assessment, development and evaluation (GRADE) approach to assess the certainty of the evidence obtained from the present meta-analysis of potential risk factors of seroconversion among COVID-19 vaccinated PLWH.

2.4. Definitions of Vaccines

The inactivated vaccines included BBIBP-CorV, Corona Vac or Sinopharm; the mRNA vaccines comprised the BNT162b2 or mRNA-1273; the adenovirus vaccines comprised the ChA-dOx1 nCoV-19 or Ad.26.COV2.S; and mixed vaccines mean more than one type of vaccine.

2.5. Statistical Analysis

The primary outcome was the odds ratio and its corresponding 95% CI of potential predictors for seroconversion to the COVID-19 vaccine in PLWH. If the outcomes were presented as RRs, data were converted to the ORs for analysis by using the formula OR = RR(1-pRef)/(1-RR×pRef), where pRef is the prevalence of the outcome in the control [18]. The p-value by χ2 test < 0.1 or the I2 statistic was ≥ 50% and was considered to indicate significant heterogeneity among the included studies. In this case, the pooled odds ratios were estimated by the fixed-effects model; otherwise, the random-effects model was preferentially performed. Subgroup analyses were conducted to evaluate the predictive value of the CD4 T-cell counts for seroconversion due to the COVID-19 vaccine according to the study location (Europe vs. America vs. Asia), study design (retrospective vs. prospective), source of data (multi-center vs. single-center), sample size (< 100 vs. ≥ 100), cut off of CD4 T-cell counts (200 cell/mm3 vs. 500 cell/mm3 vs. others), vaccine type (inactivated vaccine vs. mRNA vaccine vs. mix), and multivariable analysis (YES vs. NO). Meta-regression analyses were further performed to explore the potential effect of these parameters on the outcomes. The regression coefficient was calculated to describe the change in outcomes with explanatory variables (potential effect modifiers). The potential publication bias was evaluated by Egger’s test, and funnel plots were drawn if the studies were above 10. Trim-and-fill analyses were performed to adjust for publication bias (Egger’s test p < 0.05). Sensitivity analyses were conducted where the outcomes were recalculated by omitting one study at a time. All calculations and graphs were performed and visualized with R statistic software (3.6.3).

3. Results

3.1. Study Selection, Characteristics and Quality Assessment

The study selection is shown in Figure 1. A total of 1592 potentially relevant studies were identified through the literature search. After screening the initial titles and abstracts, the full text of 63 studies was further considered for eligibility. After the removal of another 40 studies, including 33 studies that failed to report the odds ratios, 5 cross-sectional studies, and 2 reviews (File S1), 23 studies [13,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40] that included 4428 patients living with HIV were finally included in the meta-analysis (Figure 1).
The main characteristics and clinical outcomes of the studies for quantitative analysis are summarized in Table 1. Of these studies, 11 were from Europe, 5 were from Asia, 5 were from North America, 1 was from South Africa, and 1 was from South America. The studies comprised 14 prospective studies and 9 retrospective studies. A total of 7 studies were multi-center, and 16 were single-center. The number of PLWH in 14 studies was above 100; 6 studies had adjusted for potential confounders; 7 studies were analyzed using multivariable analysis; all PLWH in the 19 studies were not infected with COVID-19 prior to vaccination. In terms of vaccination type, the mRNA vaccines were used in 11 studies; adenovirus vaccines were used in 1 study; inactivated vaccines were used in 6 studies; and another 5 studies involved two or more vaccines or other types of vaccines. PLWH, in 2 studies, received an incomplete dose of vaccines; 20 studies received a complete dose of vaccines; only 1 study received the booster dose of vaccines. Supplementary Table S2 shows the detailed risk of bias for each study, and most of the studies were regarded as critical or at a high risk of bias.

3.2. Risk Factors for Seroconversion Rate in PLWH

A summary of the findings from the included studies is shown in Figure 2. A total of 7, 7, 16, 7, 3, and 7 studies provided data for the age, gender, CD4 T-cell counts, HIV viral load, comorbidities and days after complete vaccination, respectively (Figures S1A, S2A, S3A, S4A, S5A and S6A). The pooled data showed that there were no statistical differences in seroconversion among patients with different ages, gender, HIV viral load, comorbidities and days after their complete vaccination. Notably, seroconversion was about 4.6 times in patients with higher CD4 T-cell counts (OR = 4.64, 95% CI 2.63 to 8.19) compared with those with lower CD4 T-cell counts. Quantitative synthesis was also accessible for different vaccine types, including mRNA vaccines vs. other vaccines and mRNA-1273 vs. BNT126b2 vaccines (another mRNA vaccine) (Figures S7A and S8A). The pooled data demonstrated that there was no difference in seroconversion between patients receiving the mRNA-1273 vaccines and those receiving the BNT126b2 vaccines. It is worth noting that seroconversion was about 17.5 times in patients receiving mRNA COVID-19 vaccines (OR = 17.48, 95% CI 6.16 to 49.55), compared with those receiving other types of COVID-19 vaccines.

3.3. Publication Bias

Egger’s test detected the existence of publication bias in potential predictors for seroconversion due to COVID-19 vaccines, including the CD4 T-cell counts (p < 0.01) and HIV viral load (p = 0.02). The funnel plot also showed the relative asymmetry in CD4 T-cell counts (Figure S3B). After eight studies were filled, the funnel plot showed relative symmetry (Figure S3C), and Egger’s test showed no evidence of significant publication bias (p = 0.60). Patients with high CD4 T-cell counts still had higher seroconversions than those with low CD4 T-cell counts (OR = 1.85, 95% CI 1.05 to 3.28). As for the HIV viral load, after three studies were filled, Egger’s test showed no evidence of significant publication bias (p = 0.78) (Figure S4C) with still no statistical difference in the seroconversions among patients with different HIV viral loads (OR = 1.30, 95% CI 0.40 to 4.21).

3.4. Meta-Regression and Subgroup Analysis

Considering the potential predictive value of the CD4 T-cell counts in seroconversion due to the COVID-19 vaccines in PLWH, univariate meta-regression and subgroup analyses were further carried out to explore the source of heterogeneity. The univariate meta-regression found no significant moderators of heterogeneity (Table S3). All the subgroup analyses arrived at a consistent conclusion (OR range, 2.30 to 9.59) (Figure 3 and Figures S9–S15). Interestingly, a subgroup analysis, conducted according to the cutoff of CD4 T-cell counts, demonstrated that the odds ratio was highest in the cutoff for 200 cell/mm3 (OR = 6.18, 95% CI 2.98 to 12.84), followed by the cutoff for others (OR = 5.80, 95% CI 2.04 to 16.48), and a cutoff for 500 cell/mm3 (OR = 2.30, 95% CI 1.45 to 3.64) (p = 0.04) (Figure 3 and Figure S13). Subgroup analysis, stratified by vaccine type, showed that the odds ratio was lowest when patients received the inactivated vaccine (OR = 2.90, 95% CI 1.64 to 5.11), followed by the mRNA vaccine (OR = 5.38, 95% CI 1.77 to 16.32), and mixed vaccines-type (OR = 8.76, 95% CI 4.81 to 15.95) (p = 0.03) (Figure 3 and Figure S14). No significant heterogeneity was observed in the other subgroup comparisons (all p > 0.05).

3.5. Sensitivity Analysis

The sensitivity analysis, performed by using the “leave-one-out”, did not markedly change our results in these comparisons (Figures S1–S8).

3.6. Grading the Quality of Evidence

According to the GRADE approach, the quality of evidence was very low for age, gender, CD4 T-cell counts, HIV viral load, comorbidities, days after complete vaccination, and vaccine-type impact factors (Table S4).

4. Discussion

In this meta-analysis, 23 studies with a total of 4428 patients living with HIV were included. We evaluated the potential factors for predicting seroconversion due to the COVID-19 vaccine in PLWH. We demonstrated that the CD4 T-cell counts and mRNA vaccines are associated with seroconversion due to COVID-19 vaccination. Compared with the PLWH with lower CD4 T-cell counts, the seroconversion rate was about 4.6 times in patients with higher CD4 T-cell counts. The mRNA COVID-19-vaccinated PLWH showed about 17.5 times the seroconversion compared with those receiving other types of COVID-19 vaccines, such as the inactivated vaccines. Advanced age, gender, HIV viral load, comorbidities, days after complete vaccination, and different mRNA vaccine types showed no association with seroconversion. The subgroup analysis further validated our finding about the predictive value of CD4 T-cell counts for seroconversion in PLWH.
An effective COVID-19 vaccination strategy becomes the main measure of reducing the risk and mortality of COVID-19 [1]. Immunocompromised patients are of particular interest because of their attenuated responses to various vaccines [41,42,43]. There are several meta-analyses reporting seroconversion due to the COVID-19 vaccine in immunocompromised patients, including PLWH. For example, Mehrabi Nejad et al., demonstrated that immunocompromised patients had a lower overall crude prevalence of seroconversion. Notably, transplant patients were less likely to develop seroconversion after both the first and second dose compared with patients with malignancy or autoimmune disease [44]. However, this study did not include PLWH and also failed to evaluate the risk factors for seroconversion. Yin et al., mainly focused on the PLWH and reported that a second dose could consistently improve the seroconversion, although the seroconversion is still lower in PLWH than in healthy individuals [45]. Conversely, Kang et al., considered the immunogenicity and safety of the COVID-19 vaccine in PLWH to be acceptable because there were no significant differences in the seroconversion rates and incidence rates of adverse events of COVID-19 vaccines between PLWH and healthy controls [46]. However, these two studies still failed to evaluate the risk factors for seroconversion in PLWH. In our study, we comprehensively evaluated the potential risk factors for seroconversion due to the COVID-19 vaccine in PLWH, including age, gender, CD4 T-cell counts, HIV viral load, comorbidities, days after complete days, and vaccine type. We finally found that the CD4 T-cell counts and vaccine type are associated with seroconversion due to COVID-19 vaccination. Our findings were completely different from previous meta-analyses and filled a gap in the risk factors for seroconversion due to the COVID-19 vaccine. PLWH are characterized by impaired immunity with reduced CD4 T-cell counts. For the generation of antibody response to vaccination, an essential step is the interaction of antigen-primed B cells and CD4 T-cells in the germinal center reaction, where CD4 T-cells provide critical helper function for the B cells to undergo proliferation, isotype switching and somatic hypermutation [47,48]. Despite antiretroviral therapy, the immune dysfunction may not be completely reversed [13]. Therefore, PLWH could have decreased response to vaccination due to defects of CD4 T-cells’ help [49,50]. Previous studies showed considerably weaker responses among PLWH with CD4 T-cell counts of < 300 cells/mm3 compared with HIV-negative individuals [19,26,30,51]. Some studies found similar humoral immune responses in PLWH with CD4 T-cell counts of > 500 cells/mm3 compared to the health controls [19,31]. Here, we found that the CD4 T-cell counts are associated with seroconversion in COVID-19-vaccinated PLWH. More importantly, we found that the odds ratio was higher in the cutoff for 200 cell/mm3 than in the cutoff for 500 cell/mm3. These results suggested that lower CD4 T-cell counts predict lower seroconversion in COVID-19-vaccinated PLWH.
It is also worth noting that the mRNA vaccine developed the highest serologic response in PLWH than the inactivated and adenovirus vaccines, which suggested PLWH are given priority for the mRNA vaccine. This finding was consistent with the results from general patients [52,53]. For example, previous studies demonstrated that compared with the mRNA vaccine, the antibody level of inactivated CoronaVac-vaccinees wanes quickly, and patients after the vaccine face a higher risk of breakthrough infection [54,55]. Further, the geometric NAbTs of inactivated vaccinees were 19-fold lower than that of the BNT162b2-vaccines [56,57]. The mRNA vaccines also showed superior cellular immune responses when compared to other vaccines against SARS-CoV-2 [58]. The median levels of CD4 responses following the mRNA vaccine were higher than the adenoviral vaccine, followed by the inactivated vaccine [58]. In a recent UK population-based study, the mRNA BNT162b2 vaccine showed to be more efficacious than the adenovirus ChA-dOx1 nCoV-19 vaccine against SARS-CoV-2 infection and hospital admissions for COVID-19 [59]. Our findings suggest that, just like the general population, PLWH respond better to the mRNA vaccines than other vaccines.
This systematic review and meta-analysis had some limitations. First, some of the studies included were observational studies, which might cause a risk of unbalanced groups for comparison with a high risk of bias. Second, significant heterogeneity and publication bias were found in some analyses, while the outcomes of trim-and-fill analyses, sensitivity analyses, and subgroup analyses were consistent. Third, ART is fundamental to the clinical care of PLWH, while the association between ART and seroconversion in PLWH was not evaluated due to a lack of data. Fourth, we did not evaluate the predictive value of the nadir CD4 counts for the seroconversion in PLWH due to data unavailability. Finally, the subgroup analysis was only performed for the CD4 T-cell counts but not other potential predictors due to fewer than 10 studies. Numerous studies are needed to pool the potential predictors for seroconversion due to the COVID-19 vaccine in PLWH.

5. Conclusions

CD4 T-cell counts are associated with seroconversion in COVID-19-vaccinated PLWH. Precautions should be emphasized in these patients with low CD4 T-cell counts, even after a complete vaccination course. Moreover, the mRNA vaccines might be a priority for PLWH with COVID-19.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines11040789/s1, Figures S1–S8. The forest plot, sensitivity analysis, and publication bias analysis for the pooled odds ratio of age, gender, CD4 T-cell counts, HIV viral load, comorbidities, days after complete vaccination, vaccine type, and mRNA vaccine type associated with serologic response in PLWH after COVID-19 vaccination respectively; Figures S9–S15. Subgroup analysis according to study location, study design, source of data, sample size, CD4 T-cell counts strata, vaccine type, and logistic regression analysis type respectively for the pooled odds ratio of CD4 T-cell counts associated with serologic response in PLWH after COVID-19 vaccination; Table S1. Search strategy; Table S2. Risk of bias of all included studies; Table S3. Meta-regression for odds ratio for the seroconversion in COVID-19 vaccinated PLWH with high and low CD4 T cells; Table S4. Certainty of evidence and summary effect estimates assessed by GRADE; File S1. List of excluded studies.

Author Contributions

Conceptualization, H.L. and G.D.; methodology, Q.Z.; software, Q.Z.; validation, F.Z., Y.M. and G.D.; formal analysis, Q.Z.; investigation, Q.Z. and Y.L.; resources, Q.Z. and Y.L.; data curation, Q.Z.; writing—original draft preparation, Q.Z.; writing—review and editing, Y.L., F.Z., Y.M. and G.D.; visualization, Q.Z.; supervision, H.L. and G.D.; project administration, Q.Z.; funding acquisition, F.Z. and G.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research is supported by the National Natural Science Foundation of China (no. 82102803, 82103183, 82272849) and Natural Science Foundation of Hunan province (no. 2021JJ40976, 2022JJ40767).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data supporting this study’s findings are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
  2. Geretti, A.M.; Stockdale, A.J.; Kelly, S.H.; Cevik, M.; Collins, S.; Waters, L.; Villa, G.; Docherty, A.; Harrison, E.M.; Turtle, L.; et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin. Infect. Dis. 2021, 73, e2095–e2106. [Google Scholar] [CrossRef] [PubMed]
  3. Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin. Infect. Dis. 2021, 73, e2005–e2015. [Google Scholar] [CrossRef] [PubMed]
  4. Bhaskaran, K.; Rentsch, C.T.; MacKenna, B.; Schultze, A.; Mehrkar, A.; Bates, C.J.; Eggo, R.M.; Morton, C.E.; Bacon, S.C.J.; Inglesby, P.; et al. HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 2021, 8, e24–e32. [Google Scholar] [CrossRef]
  5. Tesoriero, J.M.; Swain, C.-A.E.; Pierce, J.L.; Zamboni, L.; Wu, M.; Holtgrave, D.R.; Gonzalez, C.J.; Udo, T.; Morne, J.E.; Hart-Malloy, R.; et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw. Open 2021, 4, e2037069. [Google Scholar] [CrossRef]
  6. Balcells, M.E.; Le Corre, N.; Durán, J.; Ceballos, M.E.; Vizcaya, C.; Mondaca, S.; Dib, M.; Rabagliati, R.; Sarmiento, M.; Burgos, P.I.; et al. Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile. Clin. Infect. Dis. 2022, 75, e594–e602. [Google Scholar] [CrossRef]
  7. Huang, X.; Yan, Y.; Su, B.; Xiao, D.; Yu, M.; Jin, X.; Duan, J.; Zhang, X.; Zheng, S.; Fang, Y.; et al. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. Viruses 2022, 14, 277. [Google Scholar] [CrossRef]
  8. Yan, Y.; Davgadorj, C.; Lyu, C.; Zhang, S.; Qiu, Y. Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study. J. Infect. 2022, 85, e109–e111. [Google Scholar] [CrossRef]
  9. Chan, D.P.C.; Wong, N.S.; Wong, B.C.; Chan, J.M.; Lee, S.S. Three-Dose Primary Series of Inactivated COVID-19 Vaccine for Persons Living with HIV, Hong Kong. Emerg. Infect. Dis. 2022, 28, 2130–2132. [Google Scholar] [CrossRef]
  10. Hafiz, I.; Illian, D.N.; Meila, O.; Utomo, A.R.H.; Susilowati, A.; Susetya, I.E.; Desrita, D.; Siregar, G.A.; Basyuni, M. Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. Vaccines 2022, 10, 82. [Google Scholar] [CrossRef]
  11. Hasan, T.; Beardsley, J.; Marais, B.; Nguyen, T.; Fox, G. The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines. Vaccines 2021, 9, 326. [Google Scholar] [CrossRef]
  12. Petráš, M.; Máčalík, R.; Janovská, D.; Čelko, A.M.; Dáňová, J.; Selinger, E.; Doleček, J.; Neradová, S.; Franklová, M.; Dlouhý, P.; et al. Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: A meta-analysis and meta-regression. BMC Med. 2022, 20, 461. [Google Scholar] [CrossRef]
  13. Corma-Gómez, A.; Fernández-Fuertes, M.; García, E.; Fuentes-López, A.; Gómez-Ayerbe, C.; Rivero-Juárez, A.; Domínguez, C.; Santos, M.; Viñuela, L.; Palacios, R.; et al. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clin. Microbiol. Infect. 2022, 28, 1492–1498. [Google Scholar] [CrossRef]
  14. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
  15. Dekkers, O.M.; Egger, M.; Altman, D.G.; Vandenbroucke, J.P. Distinguishing Case Series From Cohort Studies. Ann. Intern. Med. 2012, 156, 37–40. [Google Scholar] [CrossRef]
  16. Higgins, J.P.T.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savović, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.C.; et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343, d5928. [Google Scholar] [CrossRef] [Green Version]
  17. Sterne, J.A.C.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016, 355, i4919. [Google Scholar] [CrossRef] [Green Version]
  18. Ziff, M.; Lane, D.A.; Samra, M.; Griffith, M.; Kirchhof, P.; Lip, G.Y.H.; Steeds, R.; Townend, J.; Kotecha, D. Safety and efficacy of digoxin: Systematic review and meta-analysis of observational and controlled trial data. BMJ 2015, 351, h4451. [Google Scholar] [CrossRef] [Green Version]
  19. Antinori, A.; Cicalini, S.; Meschi, S.; Bordoni, V.; Lorenzini, P.; Vergori, A.; Lanini, S.; De Pascale, L.; Matusali, G.; Mariotti, D.; et al. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clin. Infect. Dis. 2022, 75, e552–e563. [Google Scholar] [CrossRef]
  20. Ao, L.; Lu, T.; Cao, Y.; Chen, Z.; Wang, Y.; Li, Z.; Ren, X.; Xu, P.; Peng, M.; Chen, M.; et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV. Emerg. Microbes Infect. 2022, 11, 1126–1134. [Google Scholar] [CrossRef]
  21. Bergman, P.; Blennow, O.; Hansson, L.; Mielke, S.; Nowak, P.; Chen, P.; Söderdahl, G.; Österborg, A.; Smith, C.I.E.; Wullimann, D.; et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. Ebiomedicine 2021, 74, 103705. [Google Scholar] [CrossRef] [PubMed]
  22. Brumme, Z.L.; Mwimanzi, F.; Lapointe, H.R.; Cheung, P.K.; Sang, Y.; Duncan, M.C.; Yaseen, F.; Agafitei, O.; Ennis, S.; Ng, K.; et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines 2022, 7, 28. [Google Scholar] [CrossRef] [PubMed]
  23. Gianserra, L.; Donà, M.G.; Giuliani, E.; Stingone, C.; Pontone, M.; Buonomini, A.R.; Giuliani, M.; Pimpinelli, F.; Morrone, A.; Latini, A. Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART. Vaccines 2022, 10, 1243. [Google Scholar] [CrossRef] [PubMed]
  24. Haidar, G.; Agha, M.; Bilderback, A.; Lukanski, A.; Linstrum, K.; Troyan, R.; Rothenberger, S.; McMahon, D.K.; Crandall, M.D.; Sobolewksi, M.D.; et al. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: The COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clin. Infect. Dis. 2022, 75, e630–e644. [Google Scholar] [CrossRef]
  25. Han, X.; Yu, X.; Han, Y.; Fang, Q.; Shen, C.; Liu, H.; Wang, P.; Wang, Y.; Li, X. Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China. Infect. Drug Resist. 2022, 15, 2091–2100. [Google Scholar] [CrossRef]
  26. Hassold, N.; Brichler, S.; Ouedraogo, E.; Leclerc, D.; Carroue, S.; Gater, Y.; Alloui, C.; Carbonnelle, E.; Bouchaud, O.; Mechai, F.; et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS 2022, 36, F1–F5. [Google Scholar] [CrossRef]
  27. Hensley, K.S.; Jongkees, M.J.; Geers, D.; GeurtsvanKessel, C.H.; Mueller, Y.M.; Dalm, V.A.S.H.; Papageorgiou, G.; Steggink, H.; Gorska, A.; Bogers, S.; et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in The Netherlands: A nationwide prospective cohort study. PLoS Med. 2023, 20, e1004159. [Google Scholar] [CrossRef]
  28. Khan, K.; Lustig, G.; Bernstein, M.; Archary, D.; Cele, S.; Karim, F.; Smith, M.; Ganga, Y.; Jule, Z.; Reedoy, K.; et al. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clin. Infect. Dis. 2022, 75, e857–e864. [Google Scholar] [CrossRef]
  29. Milano, E.; Ricciardi, A.; Casciaro, R.; Pallara, E.; De Vita, E.; Bavaro, D.F.; Larocca, A.M.V.; Stefanizzi, P.; Tafuri, S.; Saracino, A. Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy. J. Med. Virol. 2022, 94, 2230–2236. [Google Scholar] [CrossRef]
  30. Nault, L.; Marchitto, L.; Goyette, G.; Tremblay-Sher, D.; Fortin, C.; Martel-Laferrière, V.; Trottier, B.; Richard, J.; Durand, M.; Kaufmann, D.; et al. Covid-19 vaccine immunogenicity in people living with HIV-1. Vaccine 2022, 40, 3633–3637. [Google Scholar] [CrossRef]
  31. Netto, L.C.; Ibrahim, K.Y.; Picone, C.M.; Alves, A.P.P.S.; Aniceto, E.V.; Santiago, M.R.; Parmejani, P.S.S.; Aikawa, N.E.; Medeiros-Ribeiro, A.C.; Pasoto, S.G.; et al. Safety and immunogenicity of CoronaVac in people living with HIV: A prospective cohort study. Lancet HIV 2022, 9, e323–e331. [Google Scholar] [CrossRef]
  32. Polvere, J.; Fabbiani, M.; Pastore, G.; Rancan, I.; Rossetti, B.; Durante, M.; Zirpoli, S.; Morelli, E.; Pettini, E.; Lucchesi, S.; et al. B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV. Commun. Med. 2022, 3, 13. [Google Scholar] [CrossRef]
  33. Speich, B.; Chammartin, F.; Abela, I.A.; Amico, P.; Stoeckle, M.P.; Eichenberger, A.L.; Hasse, B.; Braun, D.L.; Schuurmans, M.M.; Müller, T.F.; et al. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clin. Infect. Dis. 2022, 75, e585–e593. [Google Scholar] [CrossRef]
  34. Spinelli, M.A.; Peluso, M.J.; Lynch, K.L.; Yun, C.; Glidden, D.V.; Henrich, T.J.; Deeks, S.G.; Gandhi, M. Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. Clin. Infect. Dis. 2022, 75, e916–e919. [Google Scholar] [CrossRef]
  35. Tuan, J.J.; Zapata, H.; Critch-Gilfillan, T.; Ryall, L.; Turcotte, B.; Mutic, S.; Andrews, L.; Roh, M.E.; Friedland, G.; Barakat, L.; et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. HIV Med. 2022, 23, 178–185. [Google Scholar] [CrossRef]
  36. Vergori, A.; Cozzi-Lepri, A.; Matusali, G.; Colavita, F.; Cicalini, S.; Gallì, P.; Garbuglia, A.R.; Fusto, M.; Puro, V.; Maggi, F.; et al. SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH. Viruses 2022, 14, 1710. [Google Scholar] [CrossRef]
  37. Wong, N.S.; Wong, B.C.K.; Chan, J.M.C.; Wong, K.H.; Tsang, O.T.Y.; Mok, C.K.P.; Hui, D.S.C.; Lee, S.S.; Chan, D.P.C. Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: Comparison between inactivated and mRNA vaccine. AIDS 2022, 36, 1255–1264. [Google Scholar] [CrossRef]
  38. Xu, X.; Vesterbacka, J.; Aleman, S.; Nowak, P. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV-but HIV viremia matters? AIDS 2022, 36, 479–481. [Google Scholar] [CrossRef]
  39. Zeng, G.; Xu, L.; Feng, S.; Tang, J.; Wang, X.; Li, G.; Gan, Y.; Zheng, C.; Zhao, J.; Yang, Z. IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China. Vaccines 2022, 10, 880. [Google Scholar] [CrossRef]
  40. Zou, S.; Wu, M.; Ming, F.; Wu, S.; Guo, W.; Marley, G.; Xing, Z.; Zhang, Z.; Zeng, M.; Sun, C.; et al. Immune response and safety to inactivated COVID-19 vaccine: A comparison between people living with HIV and HIV-naive individuals. AIDS Res. Ther. 2022, 19, 33. [Google Scholar] [CrossRef]
  41. Catherine, F.-X.; Piroth, L. Hepatitis B virus vaccination in HIV-infected people: A review. Hum. Vaccines Immunother. 2017, 13, 1304–1313. [Google Scholar] [CrossRef] [PubMed]
  42. Pallikkuth, S.; De Armas, L.R.; Pahwa, R.; Rinaldi, S.; George, V.K.; Sanchez, C.M.; Pan, L.; Dickinson, G.; Rodriguez, A.; Fischl, M.; et al. Impact of aging and HIV infection on serologic response to seasonal influenza vaccination. AIDS 2018, 32, 1085–1094. [Google Scholar] [CrossRef] [PubMed]
  43. Grohskopf, L.A.; Alyanak, E.; Broder, K.R.; Walter, E.B.; Fry, A.M.; Jernigan, D.B. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2019–2020 Influenza Season. MMWR. Recomm. Rep. 2019, 68, 1–21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Nejad, M.-M.M.; Shobeiri, P.; Dehghanbanadaki, H.; Tabary, M.; Aryannejad, A.; Ghadery, A.H.; Shabani, M.; Moosaie, F.; SeyedAlinaghi, S.; Rezaei, N. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: A systematic review and meta-analysis. Virol. J. 2022, 19, 132. [Google Scholar] [CrossRef]
  45. Yin, J.; Chen, Y.; Li, Y.; Wang, C.; Zhang, X. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: A systematic review and meta-analysis. Int. J. Infect. Dis. 2022, 124, 212–223. [Google Scholar] [CrossRef]
  46. Kang, L.; Shang, W.; Gao, P.; Wang, Y.; Liu, J.; Liu, M. Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis. Vaccines 2022, 10, 1569. [Google Scholar] [CrossRef]
  47. Zotos, D.; Coquet, J.M.; Zhang, Y.; Light, A.; D’Costa, K.; Kallies, A.; Corcoran, L.M.; Godfrey, D.I.; Toellner, K.-M.; Smyth, M.J.; et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell–intrinsic mechanism. J. Exp. Med. 2010, 207, 365–378. [Google Scholar] [CrossRef] [Green Version]
  48. Ruddy, J.A.; Boyarsky, B.J.; Werbel, W.A.; Bailey, J.R.; Karaba, A.H.; Garonzik-Wang, J.M.; Segev, D.L.; Durand, C.M. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. AIDS 2021, 35, 1872–1874. [Google Scholar] [CrossRef]
  49. Avelino-Silva, V.I.; Miyaji, K.T.; Hunt, P.W.; Huang, Y.; Simoes, M.; Lima, S.B.; Freire, M.S.; Caiaffa-Filho, H.H.; Hong, M.A.; Costa, D.A.; et al. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Negl. Trop. Dis. 2016, 10, e0005219. [Google Scholar] [CrossRef] [Green Version]
  50. Parmigiani, A.; Alcaide, M.L.; Freguja, R.; Pallikkuth, S.; Frasca, D.; Fischl, M.A.; Pahwa, S. Impaired Antibody Response to Influenza Vaccine in HIV-Infected and Uninfected Aging Women Is Associated with Immune Activation and Inflammation. PLoS ONE 2013, 8, e79816. [Google Scholar] [CrossRef]
  51. Heftdal, L.D.; Knudsen, A.D.; Hamm, S.R.; Hansen, C.B.; Møller, D.L.; Pries-Heje, M.; Fogh, K.; Hasselbalch, R.B.; Jarlhelt, I.; Pérez-Alós, L.; et al. Humoral response to two doses of BNT162b2 vaccination in people with HIV. J. Intern. Med. 2022, 291, 513–518. [Google Scholar] [CrossRef]
  52. Fedele, G.; Trentini, F.; Schiavoni, I.; Abrignani, S.; Antonelli, G.; Baldo, V.; Baldovin, T.; Bandera, A.; Bonura, F.; Clerici, P.; et al. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Front. Immunol. 2022, 13, 1021396. [Google Scholar] [CrossRef]
  53. Maringer, Y.; Nelde, A.; Schroeder, S.M.; Schuhmacher, J.; Hörber, S.; Peter, A.; Karbach, J.; Jäger, E.; Walz, J.S. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci. Immunol. 2022, 7, 78. [Google Scholar] [CrossRef]
  54. Kwok, S.L.; Cheng, S.M.; Leung, J.N.; Leung, K.; Lee, C.-K.; Peiris, J.M.; Wu, J.T. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Eurosurveillance 2022, 27, 2101197. [Google Scholar] [CrossRef]
  55. Peng, Q.; Zhou, R.; Wang, Y.; Zhao, M.; Liu, N.; Li, S.; Huang, H.; Yang, D.; Au, K.-K.; Wang, H.; et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. Ebiomedicine 2022, 77, 103904. [Google Scholar] [CrossRef]
  56. Lim, W.W.; Mak, L.; Leung, G.M.; Cowling, B.J.; Peiris, M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2021, 2, e423. [Google Scholar] [CrossRef]
  57. Chen, Y.; Shen, H.; Huang, R.; Tong, X.; Wu, C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect. Dis. 2021, 21, 1071–1072. [Google Scholar] [CrossRef]
  58. Ben Ahmed, M.; Bellali, H.; Gdoura, M.; Zamali, I.; Kallala, O.; Ben Hmid, A.; Hamdi, W.; Ayari, H.; Fares, H.; Mechri, K.; et al. Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa). Vaccines 2022, 10, 1189. [Google Scholar] [CrossRef]
  59. Wei, J.; Zhang, W.; Doherty, M.; Wallace, Z.S.; Sparks, J.A.; Lu, N.; Li, X.; Zeng, C.; Lei, G. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19. BMC Med. 2023, 21, 78. [Google Scholar] [CrossRef]
Vaccines 11 00789 g001 550
Figure 1. Flowcharts illustrating the article selection process.
Figure 1. Flowcharts illustrating the article selection process.
Vaccines 11 00789 g001
Vaccines 11 00789 g002 550
Figure 2. The pooled odds ratio of potential factors associated with seroconversion rate in people living with HIV(PLWH). Comorbidities mean PLWH with cirrhosis, HBV or HCV coinfections.
Figure 2. The pooled odds ratio of potential factors associated with seroconversion rate in people living with HIV(PLWH). Comorbidities mean PLWH with cirrhosis, HBV or HCV coinfections.
Vaccines 11 00789 g002
Vaccines 11 00789 g003 550
Figure 3. The pooled odds ratio of CD4 T-cell counts in subgroup analyses.
Figure 3. The pooled odds ratio of CD4 T-cell counts in subgroup analyses.
Vaccines 11 00789 g003
Table
Table 1. Characteristics of included studies.
Table 1. Characteristics of included studies.
SourceCountryDesignData SourceCasesVaccine TypeVaccine DoseCOVID-19 HistoryOutcomesMultivariable AnalysisImpact FactorsAdjust
Anais 2022 [13]SpainProThree university hospitals in Southern Spain420BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad26.COV2.SCompleteNOanti-S IgGYESAge, gender, HIV infection way, CDC clinical category
nadir CD4 T-cell counts,
Charlson index, cirrhosis, chronic kidney disease, immunosuppressive therapy, CD4 T-cell counts (cutoff = 200 cell/mm3), HIV viral load, vaccine		-
Antinori
2022 [19]		ItalyProNational Institute for Infectious Diseases Lazzaro Spallanzani153BNT162b2 or mRNA-1273CompleteNOnAbsNOCD4 T-cell counts (cutoff = 200 cell/mm3)-
Ao
2022 [20]		ChinaProPeople’s Hospital of Tongliang District139BBIBP-CorV or Corona Vac CompleteNO anti-RBD IgGYESAge, gender, days after 2nd vaccination, CD4 T-cell counts (cutoff = 500 cell/mm3), HIV viral load, white blood cell count, lymphocyte count, platelet count, alanine aminotransferase, aspartate aminotransferase, B cells, RBD-specific B cells, RBD-specific MBCs, RBD+ rMBCs, RBD+ actMBCs, RBD+ atyMBCs, RBD+ intMBCs-
Bergman
2021 [21]		SwedenProKarolinska University Hospital79BNT162b2CompleteNOanti-RBD IgGNOCD4 T-cell counts (cutoff = 300 cell/mm3)Age (partially)
Brumme
2022 [22]		CanadaRetroThree HIV care clinics in 100BNT162b2, mRNA-1273 or ChAdOx1CompleteYESanti-RBD IgGNODays after 2nd vaccinationAge,
chronic health conditions
Gianserra
2022 [23]		ItalyProHIV/AIDS Unit of the San Gallicano Dermatological Institute42BNT162b2CompleteNOSARS-CoV-2 S1/S2 IgGNODays after second vaccination-
Haidar
2022 [24]		USAProUnive University of Pittsburgh Medical Center Health System94BNT162b2, mRNA-1273 or AdenovirusCompleteNOanti-RBD IgGNO, except for days after 2nd doseAge, gender, race, vaccine, days after second dose-
Han
2022 [25]		ChinaRetroBeijing Ditan Hospital47CoronaVac or SinopharmCompleteNOnAbsNOCD4 T-cell counts (cutoff = 350 cell/mm3)Age, sex,
and interval length
Hassold
2022 [26]		France RetroDepartment of Infectious Diseases of Hospital Avicenne105BNT162b2, mRNA-1273 or ChAdOx1-nCoV-19CompleteNOAnti-spike IgGNOCD4 T-cell counts (cutoff = 200 cell/mm3)-
Hensley
2022 [27]		NetherlandsPro22 HIV treatment centers1154BNT162b2, mRNA-1273, ChAdOx1-S or Ad26.COV2.SCompleteNOAnti-spike IgGYES, except for vaccine typeVaccine type, age, gender, HIV viral load, CD4 T-cell counts (cutoff = 250 cell/mm3), CD4 nadir cell counts-
Khan
2022 [28]		South AfricanProBiomedical Research of the University of KwaZulu–Natal26Ad26.CoV2.SCompleteYESNeutralization capacityNOHIV viral load-
Milano
2022 [29]		ItalyProUniversity of Bari578BNT162b2CompleteNOAnti-RBD IgGNODays after complete vaccination -
Nault 2022 [30]CanadaRetroHIV clinics in Montreal106mRNA-1273UncompleteYESAnti-RBD IgGNOCD4 T-cell counts (cutoff = 250 cell/mm3)-
Netto
2022 [31]		BrazilProUniversity of Sao Paulo HIV/AIDS outpatient clinic215CoronaVacCompleteNOnAbsNOCD4 T-cell counts (cutoff = 500 cell/mm3)-
Polvere
2022 [32]		ItalyRetroAzienda Ospedaliera Universitaria Senese84BNT162b2 or mRNA-1273CompleteNOnAbsNOAge, gender, vaccine type, BMI, IDU, years from HIV infection, CDC stage, HBV or HCV coinfection,
zenith HIV-RNA,
CD4 T-cell counts at nadir, years from first ART, type of ART, HIV viral load, time from last HIV-RNA >50 copies/mL, CD4 T-cell counts at baseline (cutoff = 350 cell/mm3), CD4%, CD4/CD8 ratio 		-
Speich
2022 [33]		SwitzerlandRCTUniversity Hospital Basel, University Hospital Bern and University Hospital Zurich341BNT162b2 or mRNA-1273CompleteYESnAbsNOVaccine typeRCT
Spinelli 2022 [34]USARetroA large outpatient HIV clinic100BNT162b2 or mRNA-1273CompleteNOnAbsYESCD4 T-cell counts (cutoff = NA), HIV viral load, vaccine typeCare for chronic medical conditions on days since completion of second vaccination (minimum 10), sex, age and mRNA vaccine type
Tuan
2022 [35]
USARetroTwo HIV clinics of the Yale New Haven Health System78BNT162b2UncompleteNOIgG
NO, except for CD4 T-cell countsAge, gender, days after second vaccination, BMI, self-reported
substance use, time
since HIV diagnosis, HIV ART regimen,
CD4 T-cell counts (cutoff = 500 cell/mm3), HIV viral load, comorbidities		-
Vergori
2022 [36]		ItalyRetroInfectious Diseases Lazzaro Spallanzani in Rome106BNT162b2 or Mrna-1273BoosterNOnAbsNOCD4 T-cell counts (cutoff = 200 cell/mm3), CD4 T-cell counts at nadir-
Wong
2022 [37]		ChinaProThe Integrated Treatment Centre or Princess Margaret Hospital HIV Service213CoronaVac or ComirnatyCompleteNOnAbsNOVaccine typeage, sex, CD4 T-cell counts, and suppressed viral load (SVL) at the time point nearest to vaccination.
Xu
2022 [38]		SwedenProKarolinska University Hospital79BNT162b2CompleteNOanti-spike-IgGNOCD4 T-cell counts (cutoff = 200 cell/mm3)-
Zeng
2022 [39]		ChinaRetroThe Third People’s Hospital of Shenzhen126BBIBP-CorV or CoronaVac CompleteNOanti-RBD IgGNO
CD4 T-cell counts (cutoff = 350 cell/mm3), days after complete vaccination, vaccine type-
Zou
2022 [40]		ChinaProWuchang district of Wuhan city46Sinopharm WIBP-CorVCompleteNOnAbs
and IgG		YES, except for days after 2nd doseAge, gender, CD4 T-cell counts (cutoff = NA), days after second dose-
Abbreviations: COVID-19, coronavirus disease 2019; Pro, prospective study; Retro, retrospective study; RCT, randomized controlled trial; RBD, receptor binding domain; Ig, immunoglobulin; S, spike; nAbs, neutralizing antibodies; BMI, body mass index; MBC, memory B cell; BV, hepatitis B virus; HCV, hepatitis C virus; IDU, injecting drug users; NA, not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhou, Q.; Liu, Y.; Zeng, F.; Meng, Y.; Liu, H.; Deng, G. Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis. Vaccines 2023, 11, 789. https://doi.org/10.3390/vaccines11040789

AMA Style

Zhou Q, Liu Y, Zeng F, Meng Y, Liu H, Deng G. Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis. Vaccines. 2023; 11(4):789. https://doi.org/10.3390/vaccines11040789

Chicago/Turabian Style

Zhou, Qian, Yihuang Liu, Furong Zeng, Yu Meng, Hong Liu, and Guangtong Deng. 2023. "Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis" Vaccines 11, no. 4: 789. https://doi.org/10.3390/vaccines11040789

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop